Staidson (Beijing) BioPharmaceuticals Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Wang Chao
Chief executive officer
CN¥1.4m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 3.4yrs |
| CEO ownership | 0.08% |
| Management average tenure | no data |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SZSE:300204) Stock Rockets 47% As Investors Are Less Pessimistic Than Expected
Oct 08
Subdued Growth No Barrier To Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SZSE:300204) With Shares Advancing 26%
Aug 03There's Reason For Concern Over Staidson (Beijing) BioPharmaceuticals Co., Ltd.'s (SZSE:300204) Massive 26% Price Jump
Aug 02What Staidson (Beijing) BioPharmaceuticals Co., Ltd.'s (SZSE:300204) 25% Share Price Gain Is Not Telling You
Mar 18CEO
Wang Chao (42 yo)
3.4yrs
Tenure
CN¥1,362,100
Compensation
Mr. Wang Chao is General Manager of Staidson (Beijing) BioPharmaceuticals Co. Ltd. from August 2021.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 15.7yrs | CN¥1.30m | 1.1% CN¥ 37.9m | |
| Supervisor | 13.9yrs | CN¥168.10k | no data | |
| Chairman of Supervisory Board | 6.3yrs | CN¥240.00k | 0.098% CN¥ 3.4m | |
| Non-Independent Director | 6.3yrs | CN¥1.70m | 0.21% CN¥ 7.1m | |
| Non-Independent Director | 3.4yrs | CN¥1.60m | 0.075% CN¥ 2.6m | |
| Independent Director | 3.4yrs | CN¥136.80k | no data | |
| Independent Director | 3.4yrs | CN¥136.80k | no data | |
| Employee Supervisor | 3.4yrs | no data | 0.024% CN¥ 824.5k | |
| Director | 2.3yrs | no data | no data |
3.4yrs
Average Tenure
59yo
Average Age
Experienced Board: 300204's board of directors are considered experienced (3.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 14:40 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Staidson (Beijing) BioPharmaceuticals Co., Ltd. is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xin Zhang | AJ Securities Co., Ltd |
| YANG QIAO | Changjiang Securities Co. LTD. |
| Ling Bo Tu | China Minzu Securities |